| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitochondrial Diseases | 33 | 2025 | 132 | 10.400 |
Why?
|
| DNA, Mitochondrial | 26 | 2024 | 211 | 4.580 |
Why?
|
| MELAS Syndrome | 9 | 2023 | 33 | 3.500 |
Why?
|
| Mitochondria | 21 | 2024 | 680 | 2.840 |
Why?
|
| Congenital Disorders of Glycosylation | 8 | 2025 | 46 | 2.790 |
Why?
|
| Leigh Disease | 6 | 2021 | 24 | 2.440 |
Why?
|
| Mitochondrial Myopathies | 10 | 2024 | 28 | 2.440 |
Why?
|
| Mitochondrial Proteins | 14 | 2023 | 228 | 2.360 |
Why?
|
| Mutation | 50 | 2025 | 5842 | 2.330 |
Why?
|
| Metabolism, Inborn Errors | 11 | 2024 | 117 | 2.290 |
Why?
|
| Arginine | 9 | 2023 | 334 | 2.130 |
Why?
|
| Mitochondrial Encephalomyopathies | 7 | 2023 | 27 | 2.090 |
Why?
|
| Citrulline | 7 | 2023 | 109 | 1.830 |
Why?
|
| Phenotype | 31 | 2025 | 4262 | 1.810 |
Why?
|
| Nitric Oxide | 7 | 2017 | 493 | 1.750 |
Why?
|
| Metabolomics | 3 | 2025 | 423 | 1.570 |
Why?
|
| Cardiomyopathies | 6 | 2024 | 500 | 1.560 |
Why?
|
| Acidosis, Lactic | 5 | 2023 | 30 | 1.560 |
Why?
|
| Developmental Disabilities | 13 | 2020 | 712 | 1.560 |
Why?
|
| Carnitine | 9 | 2015 | 74 | 1.530 |
Why?
|
| Glutarates | 5 | 2024 | 37 | 1.530 |
Why?
|
| Intellectual Disability | 14 | 2025 | 1056 | 1.420 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 2 | 2021 | 22 | 1.360 |
Why?
|
| Purpura | 2 | 2021 | 24 | 1.340 |
Why?
|
| Infant | 66 | 2025 | 12504 | 1.290 |
Why?
|
| Humans | 175 | 2025 | 125167 | 1.260 |
Why?
|
| Anemia, Sideroblastic | 2 | 2021 | 17 | 1.190 |
Why?
|
| Epilepsy | 6 | 2025 | 874 | 1.180 |
Why?
|
| Child, Preschool | 62 | 2025 | 14019 | 1.120 |
Why?
|
| Spasms, Infantile | 4 | 2018 | 171 | 1.080 |
Why?
|
| Seizures | 7 | 2024 | 872 | 1.050 |
Why?
|
| Child | 73 | 2025 | 24402 | 1.020 |
Why?
|
| Chromosome Deletion | 11 | 2017 | 647 | 1.010 |
Why?
|
| Male | 100 | 2025 | 61503 | 1.000 |
Why?
|
| Dietary Supplements | 5 | 2020 | 473 | 0.990 |
Why?
|
| Carrier Proteins | 6 | 2020 | 1021 | 0.980 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1101 | 0.980 |
Why?
|
| Abnormalities, Multiple | 11 | 2022 | 960 | 0.970 |
Why?
|
| Female | 104 | 2025 | 66783 | 0.950 |
Why?
|
| Stroke | 3 | 2023 | 989 | 0.940 |
Why?
|
| Genetic Association Studies | 8 | 2019 | 779 | 0.940 |
Why?
|
| Microcephaly | 6 | 2024 | 331 | 0.930 |
Why?
|
| Liver Diseases | 3 | 2016 | 367 | 0.920 |
Why?
|
| Liver Transplantation | 10 | 2021 | 1036 | 0.900 |
Why?
|
| Symporters | 1 | 2025 | 69 | 0.900 |
Why?
|
| Brain Diseases | 3 | 2022 | 300 | 0.900 |
Why?
|
| Arginine-tRNA Ligase | 1 | 2024 | 9 | 0.890 |
Why?
|
| Brain | 12 | 2024 | 2999 | 0.870 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2024 | 32 | 0.870 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2020 | 143 | 0.850 |
Why?
|
| Ubiquinone | 5 | 2020 | 25 | 0.810 |
Why?
|
| Autism Spectrum Disorder | 3 | 2025 | 391 | 0.810 |
Why?
|
| UDPglucose 4-Epimerase | 2 | 2021 | 7 | 0.810 |
Why?
|
| Galactosemias | 2 | 2021 | 14 | 0.800 |
Why?
|
| Calcinosis | 1 | 2024 | 178 | 0.800 |
Why?
|
| Epileptic Syndromes | 1 | 2022 | 29 | 0.800 |
Why?
|
| Nervous System Malformations | 1 | 2024 | 130 | 0.790 |
Why?
|
| Epilepsy, Generalized | 1 | 2022 | 64 | 0.780 |
Why?
|
| Infant, Newborn | 35 | 2025 | 8225 | 0.770 |
Why?
|
| Adolescent | 48 | 2025 | 19350 | 0.760 |
Why?
|
| Alleles | 10 | 2019 | 1614 | 0.760 |
Why?
|
| Electron Transport | 9 | 2019 | 55 | 0.760 |
Why?
|
| Autistic Disorder | 4 | 2015 | 350 | 0.750 |
Why?
|
| Urea | 5 | 2019 | 231 | 0.740 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2021 | 3572 | 0.740 |
Why?
|
| Mitochondrial Dynamics | 2 | 2018 | 44 | 0.740 |
Why?
|
| Metabolome | 2 | 2021 | 293 | 0.740 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 6 | 2019 | 101 | 0.720 |
Why?
|
| Anemia, Macrocytic | 1 | 2020 | 8 | 0.700 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2020 | 8 | 0.700 |
Why?
|
| Riboflavin Deficiency | 1 | 2020 | 9 | 0.700 |
Why?
|
| Riboflavin | 1 | 2020 | 38 | 0.690 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 6 | 2011 | 34 | 0.650 |
Why?
|
| Enoyl-CoA Hydratase | 1 | 2019 | 5 | 0.640 |
Why?
|
| DNA Replication | 3 | 2018 | 352 | 0.630 |
Why?
|
| Genes, Recessive | 2 | 2019 | 185 | 0.620 |
Why?
|
| Metabolic Diseases | 2 | 2022 | 130 | 0.610 |
Why?
|
| Genetic Therapy | 2 | 2020 | 687 | 0.610 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2012 | 107 | 0.600 |
Why?
|
| Heterozygote | 8 | 2019 | 671 | 0.600 |
Why?
|
| Kearns-Sayre Syndrome | 2 | 2016 | 6 | 0.600 |
Why?
|
| Pyruvate Dehydrogenase Complex Deficiency Disease | 1 | 2018 | 4 | 0.600 |
Why?
|
| Adult | 39 | 2025 | 29634 | 0.600 |
Why?
|
| Muscle Weakness | 4 | 2020 | 84 | 0.600 |
Why?
|
| Gangliosidosis, GM1 | 2 | 2008 | 7 | 0.590 |
Why?
|
| Acyltransferases | 1 | 2018 | 44 | 0.590 |
Why?
|
| Aorta, Thoracic | 1 | 2023 | 533 | 0.590 |
Why?
|
| Neuromuscular Diseases | 2 | 2011 | 57 | 0.570 |
Why?
|
| Syndrome | 12 | 2022 | 1120 | 0.560 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 2 | 2014 | 20 | 0.540 |
Why?
|
| RNA, Transfer | 3 | 2021 | 72 | 0.540 |
Why?
|
| GTP Phosphohydrolases | 4 | 2019 | 147 | 0.530 |
Why?
|
| Chromosomes, Human, X | 3 | 2009 | 157 | 0.530 |
Why?
|
| Folic Acid Deficiency | 2 | 2007 | 53 | 0.520 |
Why?
|
| Graft Rejection | 2 | 2019 | 588 | 0.520 |
Why?
|
| Metal Metabolism, Inborn Errors | 1 | 2015 | 7 | 0.510 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2011 | 73 | 0.500 |
Why?
|
| Kidney Diseases | 2 | 2019 | 479 | 0.500 |
Why?
|
| Optic Atrophy | 2 | 2017 | 47 | 0.490 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2015 | 5 | 0.490 |
Why?
|
| Energy Transfer | 1 | 2015 | 16 | 0.490 |
Why?
|
| Calcium-Binding Proteins | 3 | 2017 | 326 | 0.480 |
Why?
|
| Hypertension, Pulmonary | 1 | 2020 | 440 | 0.470 |
Why?
|
| Hemochromatosis | 2 | 2014 | 33 | 0.470 |
Why?
|
| Diagnosis, Differential | 5 | 2024 | 1896 | 0.460 |
Why?
|
| Urea Cycle Disorders, Inborn | 2 | 2019 | 77 | 0.460 |
Why?
|
| Gene Deletion | 6 | 2016 | 789 | 0.440 |
Why?
|
| Muscular Diseases | 4 | 2015 | 103 | 0.440 |
Why?
|
| Young Adult | 20 | 2025 | 9056 | 0.430 |
Why?
|
| DNA Damage | 1 | 2017 | 513 | 0.430 |
Why?
|
| Membrane Proteins | 5 | 2023 | 1526 | 0.420 |
Why?
|
| Ataxia | 3 | 2022 | 170 | 0.420 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 874 | 0.410 |
Why?
|
| Genotype | 8 | 2024 | 2564 | 0.400 |
Why?
|
| Nervous System Diseases | 2 | 2015 | 375 | 0.400 |
Why?
|
| Munc18 Proteins | 1 | 2012 | 20 | 0.400 |
Why?
|
| Thymidine Phosphorylase | 2 | 2020 | 12 | 0.390 |
Why?
|
| Organic Anion Transporters | 2 | 2014 | 16 | 0.390 |
Why?
|
| Glycosylation | 4 | 2025 | 125 | 0.380 |
Why?
|
| Disease Management | 5 | 2019 | 528 | 0.380 |
Why?
|
| Biomarkers | 8 | 2020 | 3090 | 0.370 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 167 | 0.370 |
Why?
|
| Heart Diseases | 1 | 2016 | 493 | 0.370 |
Why?
|
| Muscle Hypotonia | 4 | 2024 | 187 | 0.370 |
Why?
|
| Comparative Genomic Hybridization | 9 | 2013 | 572 | 0.360 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2008 | 140 | 0.360 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2011 | 14 | 0.360 |
Why?
|
| Liver Failure | 2 | 2022 | 89 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 3157 | 0.360 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 94 | 0.350 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2011 | 294 | 0.340 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 276 | 0.340 |
Why?
|
| Antigens, CD | 1 | 2012 | 432 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 7 | 2019 | 1755 | 0.340 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 470 | 0.330 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2019 | 443 | 0.330 |
Why?
|
| Electron Transport Chain Complex Proteins | 2 | 2011 | 23 | 0.320 |
Why?
|
| Hypopigmentation | 1 | 2009 | 11 | 0.320 |
Why?
|
| Hyperammonemia | 3 | 2015 | 62 | 0.320 |
Why?
|
| Hyperargininemia | 2 | 2006 | 13 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2009 | 49 | 0.320 |
Why?
|
| Muscle, Skeletal | 6 | 2013 | 946 | 0.320 |
Why?
|
| Cell Nucleus | 1 | 2012 | 676 | 0.320 |
Why?
|
| Puberty, Precocious | 1 | 2009 | 27 | 0.310 |
Why?
|
| Mutation, Missense | 7 | 2024 | 875 | 0.310 |
Why?
|
| In Situ Hybridization, Fluorescence | 9 | 2012 | 762 | 0.310 |
Why?
|
| Triterpenes | 2 | 2020 | 21 | 0.310 |
Why?
|
| Amino Acids | 3 | 2011 | 668 | 0.310 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 157 | 0.310 |
Why?
|
| Amino Acids, Branched-Chain | 2 | 2011 | 77 | 0.300 |
Why?
|
| Animals | 20 | 2022 | 34219 | 0.300 |
Why?
|
| Cardiovascular Diseases | 2 | 2018 | 1968 | 0.300 |
Why?
|
| Phosphotransferases (Phosphomutases) | 2 | 2025 | 6 | 0.300 |
Why?
|
| Aneuploidy | 1 | 2009 | 152 | 0.300 |
Why?
|
| Exons | 5 | 2022 | 798 | 0.300 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2017 | 42 | 0.300 |
Why?
|
| Reye Syndrome | 2 | 2010 | 10 | 0.300 |
Why?
|
| Exome | 10 | 2019 | 1034 | 0.300 |
Why?
|
| beta-Galactosidase | 1 | 2008 | 147 | 0.290 |
Why?
|
| Dyskinesias | 1 | 2007 | 19 | 0.280 |
Why?
|
| Mosaicism | 1 | 2009 | 239 | 0.280 |
Why?
|
| Folic Acid | 4 | 2013 | 294 | 0.270 |
Why?
|
| Aorta | 1 | 2011 | 549 | 0.270 |
Why?
|
| Cataract | 4 | 2017 | 224 | 0.270 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2007 | 25 | 0.270 |
Why?
|
| Pedigree | 9 | 2019 | 1605 | 0.270 |
Why?
|
| DNA Copy Number Variations | 5 | 2019 | 949 | 0.270 |
Why?
|
| Mental Disorders | 3 | 2010 | 826 | 0.270 |
Why?
|
| Organic Cation Transport Proteins | 3 | 2010 | 15 | 0.270 |
Why?
|
| Retrospective Studies | 12 | 2025 | 16342 | 0.270 |
Why?
|
| Failure to Thrive | 1 | 2007 | 90 | 0.260 |
Why?
|
| Electron Transport Complex IV | 2 | 2019 | 39 | 0.260 |
Why?
|
| Antioxidants | 2 | 2020 | 369 | 0.260 |
Why?
|
| RNA Splice Sites | 2 | 2019 | 88 | 0.260 |
Why?
|
| Treatment Outcome | 11 | 2023 | 12394 | 0.250 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2005 | 19 | 0.250 |
Why?
|
| Nucleotides | 2 | 2018 | 92 | 0.250 |
Why?
|
| Fatal Outcome | 5 | 2018 | 359 | 0.250 |
Why?
|
| Pantothenic Acid | 1 | 2025 | 5 | 0.240 |
Why?
|
| Genetic Variation | 4 | 2017 | 1502 | 0.240 |
Why?
|
| Thioctic Acid | 1 | 2025 | 12 | 0.240 |
Why?
|
| Genome, Mitochondrial | 2 | 2017 | 32 | 0.240 |
Why?
|
| RNA, Transfer, Leu | 2 | 2015 | 6 | 0.240 |
Why?
|
| Leucovorin | 1 | 2005 | 49 | 0.240 |
Why?
|
| Multienzyme Complexes | 1 | 2005 | 89 | 0.240 |
Why?
|
| Dietary Proteins | 1 | 2007 | 252 | 0.240 |
Why?
|
| Biotin | 1 | 2025 | 44 | 0.240 |
Why?
|
| Central Nervous System Diseases | 1 | 2005 | 107 | 0.240 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2025 | 42 | 0.230 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 5177 | 0.230 |
Why?
|
| tRNA Methyltransferases | 2 | 2022 | 5 | 0.230 |
Why?
|
| Enzymes | 1 | 2004 | 51 | 0.230 |
Why?
|
| Dynamins | 3 | 2019 | 38 | 0.230 |
Why?
|
| Oligopeptides | 1 | 2024 | 118 | 0.230 |
Why?
|
| RNA | 1 | 2008 | 570 | 0.230 |
Why?
|
| Hyperkinesis | 1 | 2024 | 24 | 0.220 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2024 | 26 | 0.220 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2004 | 29 | 0.220 |
Why?
|
| Nitric Oxide Donors | 1 | 2023 | 22 | 0.220 |
Why?
|
| Craniofacial Abnormalities | 4 | 2017 | 240 | 0.220 |
Why?
|
| Trisomy | 1 | 2004 | 101 | 0.220 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2003 | 27 | 0.220 |
Why?
|
| DNA Mutational Analysis | 6 | 2015 | 794 | 0.220 |
Why?
|
| Nuclear Proteins | 4 | 2022 | 1265 | 0.210 |
Why?
|
| Ophthalmoplegia | 1 | 2004 | 54 | 0.210 |
Why?
|
| Iron-Sulfur Proteins | 2 | 2020 | 5 | 0.210 |
Why?
|
| Ammonia | 1 | 2003 | 75 | 0.210 |
Why?
|
| Genetic Testing | 3 | 2019 | 1002 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2013 | 1016 | 0.210 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2022 | 4 | 0.210 |
Why?
|
| Point Mutation | 2 | 2014 | 348 | 0.210 |
Why?
|
| Sequence Deletion | 4 | 2013 | 525 | 0.200 |
Why?
|
| Vitamin B 12 | 3 | 2013 | 59 | 0.200 |
Why?
|
| Dilatation | 1 | 2023 | 67 | 0.200 |
Why?
|
| Spinocerebellar Ataxias | 2 | 2013 | 252 | 0.200 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2019 | 171 | 0.200 |
Why?
|
| Homocystinuria | 2 | 2017 | 24 | 0.200 |
Why?
|
| Laryngismus | 1 | 2002 | 4 | 0.200 |
Why?
|
| Gaucher Disease | 1 | 2002 | 12 | 0.200 |
Why?
|
| Racemases and Epimerases | 1 | 2022 | 9 | 0.200 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 2 | 2022 | 399 | 0.200 |
Why?
|
| Glucosylceramidase | 1 | 2002 | 27 | 0.200 |
Why?
|
| Glutathione | 1 | 2023 | 196 | 0.200 |
Why?
|
| NADP | 1 | 2022 | 52 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 358 | 0.190 |
Why?
|
| NAD | 1 | 2022 | 45 | 0.190 |
Why?
|
| Potassium Channels, Tandem Pore Domain | 1 | 2022 | 29 | 0.190 |
Why?
|
| Niacin | 1 | 2022 | 58 | 0.190 |
Why?
|
| Molecular Sequence Data | 7 | 2016 | 3891 | 0.190 |
Why?
|
| Micrognathism | 1 | 2022 | 65 | 0.190 |
Why?
|
| Age of Onset | 4 | 2020 | 594 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 2 | 2024 | 107 | 0.190 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 452 | 0.190 |
Why?
|
| Cerebellum | 1 | 2005 | 415 | 0.190 |
Why?
|
| Middle Aged | 14 | 2025 | 26932 | 0.190 |
Why?
|
| Guanidinoacetate N-Methyltransferase | 2 | 2013 | 9 | 0.190 |
Why?
|
| Nucleotidyltransferases | 1 | 2021 | 43 | 0.190 |
Why?
|
| Hand Deformities, Congenital | 1 | 2022 | 88 | 0.190 |
Why?
|
| Creatine | 3 | 2013 | 41 | 0.190 |
Why?
|
| Gene Duplication | 4 | 2009 | 362 | 0.190 |
Why?
|
| Glycolipids | 1 | 2021 | 32 | 0.190 |
Why?
|
| Amino Acid Sequence | 4 | 2017 | 2715 | 0.180 |
Why?
|
| Chromosome Mapping | 5 | 2011 | 1078 | 0.180 |
Why?
|
| Liver Failure, Acute | 1 | 2022 | 89 | 0.180 |
Why?
|
| Meglutol | 1 | 2001 | 2 | 0.180 |
Why?
|
| Time | 1 | 2021 | 92 | 0.180 |
Why?
|
| Chromosome Breakage | 3 | 2011 | 167 | 0.180 |
Why?
|
| Transcription Factors | 6 | 2022 | 2588 | 0.180 |
Why?
|
| Coenzymes | 3 | 2005 | 11 | 0.180 |
Why?
|
| Electron-Transferring Flavoproteins | 1 | 2020 | 1 | 0.180 |
Why?
|
| Multiple Acyl Coenzyme A Dehydrogenase Deficiency | 1 | 2020 | 1 | 0.180 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2020 | 26 | 0.180 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2020 | 14 | 0.180 |
Why?
|
| Tachycardia, Ventricular | 1 | 2002 | 192 | 0.170 |
Why?
|
| Polysaccharides | 1 | 2021 | 140 | 0.170 |
Why?
|
| Dementia, Vascular | 1 | 2000 | 17 | 0.170 |
Why?
|
| Pregnancy | 6 | 2022 | 7202 | 0.170 |
Why?
|
| Case-Control Studies | 3 | 2016 | 3300 | 0.170 |
Why?
|
| Prognosis | 4 | 2020 | 4642 | 0.170 |
Why?
|
| Sodium Benzoate | 2 | 2013 | 4 | 0.170 |
Why?
|
| Propionic Acidemia | 1 | 2019 | 10 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2022 | 468 | 0.170 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2018 | 245 | 0.170 |
Why?
|
| Chromosome Duplication | 2 | 2010 | 147 | 0.160 |
Why?
|
| Biological Transport | 3 | 2015 | 356 | 0.160 |
Why?
|
| Chromosome Aberrations | 3 | 2011 | 613 | 0.160 |
Why?
|
| Peroxisomes | 2 | 2019 | 36 | 0.160 |
Why?
|
| Ehrlichiosis | 1 | 1999 | 10 | 0.160 |
Why?
|
| Aspirin | 1 | 2021 | 221 | 0.160 |
Why?
|
| Metabolic Networks and Pathways | 4 | 2019 | 187 | 0.160 |
Why?
|
| Sloths | 1 | 2019 | 1 | 0.160 |
Why?
|
| Nephrosis, Lipoid | 1 | 1999 | 11 | 0.160 |
Why?
|
| Cysteine | 2 | 2021 | 139 | 0.160 |
Why?
|
| Uridine Diphosphate Galactose | 1 | 2019 | 6 | 0.160 |
Why?
|
| Biopsy | 5 | 2019 | 1237 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2025 | 6159 | 0.160 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2019 | 8 | 0.160 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2019 | 41 | 0.160 |
Why?
|
| Cardiolipins | 2 | 2017 | 18 | 0.160 |
Why?
|
| Cells, Cultured | 6 | 2019 | 3054 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2010 | 160 | 0.160 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 2019 | 19 | 0.160 |
Why?
|
| Fever | 1 | 2021 | 298 | 0.160 |
Why?
|
| Glycine | 2 | 2013 | 168 | 0.160 |
Why?
|
| Hepatolenticular Degeneration | 2 | 2014 | 33 | 0.160 |
Why?
|
| Haploinsufficiency | 3 | 2019 | 258 | 0.160 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 221 | 0.150 |
Why?
|
| Consanguinity | 1 | 2019 | 115 | 0.150 |
Why?
|
| Gene Dosage | 3 | 2010 | 440 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 43 | 0.150 |
Why?
|
| Replication Origin | 1 | 2018 | 11 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2636 | 0.150 |
Why?
|
| Fatty Acids | 3 | 2015 | 344 | 0.150 |
Why?
|
| Optic Atrophy, Autosomal Dominant | 1 | 2018 | 9 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 212 | 0.150 |
Why?
|
| Homozygote | 4 | 2016 | 547 | 0.150 |
Why?
|
| Thymidine | 2 | 2020 | 54 | 0.150 |
Why?
|
| Sulfite Reductase (Ferredoxin) | 1 | 2017 | 2 | 0.150 |
Why?
|
| Models, Biological | 3 | 2016 | 1460 | 0.150 |
Why?
|
| Ferredoxins | 1 | 2017 | 4 | 0.150 |
Why?
|
| T-Box Domain Proteins | 1 | 2019 | 108 | 0.150 |
Why?
|
| Hypertrichosis | 1 | 2017 | 5 | 0.150 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 292 | 0.150 |
Why?
|
| Antiporters | 1 | 2017 | 32 | 0.140 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 816 | 0.140 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein U | 1 | 2017 | 7 | 0.140 |
Why?
|
| Catechin | 1 | 2017 | 13 | 0.140 |
Why?
|
| Protein Biosynthesis | 1 | 2021 | 663 | 0.140 |
Why?
|
| Eutheria | 1 | 2017 | 2 | 0.140 |
Why?
|
| Phenylbutyrates | 2 | 2011 | 58 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2013 | 731 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 293 | 0.140 |
Why?
|
| Urogenital Abnormalities | 1 | 2019 | 154 | 0.140 |
Why?
|
| Repressor Proteins | 2 | 2024 | 813 | 0.140 |
Why?
|
| Cell Cycle Proteins | 2 | 2019 | 657 | 0.130 |
Why?
|
| Tetrahydrofolates | 2 | 2007 | 17 | 0.130 |
Why?
|
| Galactosyltransferases | 1 | 2016 | 6 | 0.130 |
Why?
|
| Standard of Care | 1 | 2017 | 130 | 0.130 |
Why?
|
| Cognition Disorders | 2 | 2011 | 552 | 0.130 |
Why?
|
| Xanthine Dehydrogenase | 1 | 2015 | 2 | 0.130 |
Why?
|
| Pterins | 1 | 2015 | 6 | 0.130 |
Why?
|
| Thiosulfates | 1 | 2015 | 5 | 0.130 |
Why?
|
| Sulfite Oxidase | 1 | 2015 | 4 | 0.130 |
Why?
|
| Aldehyde Oxidase | 1 | 2015 | 6 | 0.130 |
Why?
|
| Sulfites | 1 | 2015 | 30 | 0.130 |
Why?
|
| Organophosphorus Compounds | 1 | 2015 | 23 | 0.130 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2017 | 143 | 0.120 |
Why?
|
| Rhabdomyolysis | 1 | 2016 | 37 | 0.120 |
Why?
|
| Oximes | 1 | 2015 | 55 | 0.120 |
Why?
|
| Eye Abnormalities | 1 | 2016 | 104 | 0.120 |
Why?
|
| Neonatal Screening | 3 | 2017 | 184 | 0.120 |
Why?
|
| Craniosynostoses | 1 | 2017 | 132 | 0.120 |
Why?
|
| Ribonucleoprotein, U5 Small Nuclear | 1 | 2015 | 5 | 0.120 |
Why?
|
| Base Sequence | 6 | 2016 | 3102 | 0.120 |
Why?
|
| Peptide Elongation Factors | 1 | 2015 | 12 | 0.120 |
Why?
|
| Energy Metabolism | 2 | 2020 | 766 | 0.120 |
Why?
|
| Mandibulofacial Dysostosis | 1 | 2015 | 12 | 0.120 |
Why?
|
| Argininosuccinate Synthase | 2 | 2012 | 22 | 0.120 |
Why?
|
| Demyelinating Diseases | 1 | 2015 | 64 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2019 | 383 | 0.120 |
Why?
|
| Endocrine System Diseases | 1 | 2015 | 43 | 0.120 |
Why?
|
| Hemochromatosis Protein | 1 | 2014 | 22 | 0.120 |
Why?
|
| Segmental Duplications, Genomic | 2 | 2011 | 81 | 0.120 |
Why?
|
| Computational Biology | 2 | 2017 | 810 | 0.120 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2014 | 37 | 0.120 |
Why?
|
| Cell Respiration | 1 | 2014 | 23 | 0.110 |
Why?
|
| Genes, Mitochondrial | 1 | 2014 | 17 | 0.110 |
Why?
|
| Face | 3 | 2022 | 179 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2014 | 97 | 0.110 |
Why?
|
| Transcobalamins | 1 | 2013 | 4 | 0.110 |
Why?
|
| Language Development Disorders | 2 | 2013 | 174 | 0.110 |
Why?
|
| Liver | 3 | 2011 | 1745 | 0.110 |
Why?
|
| Evolution, Molecular | 1 | 2017 | 666 | 0.110 |
Why?
|
| Genomics | 3 | 2017 | 1499 | 0.110 |
Why?
|
| Ornithine | 1 | 2013 | 31 | 0.110 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2017 | 478 | 0.110 |
Why?
|
| Proton-Coupled Folate Transporter | 1 | 2013 | 6 | 0.110 |
Why?
|
| Quality of Life | 1 | 2023 | 1940 | 0.110 |
Why?
|
| Spinal Cord | 1 | 2015 | 302 | 0.110 |
Why?
|
| Thymidine Kinase | 1 | 2013 | 95 | 0.110 |
Why?
|
| Chromatin | 1 | 2016 | 553 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2012 | 1585 | 0.100 |
Why?
|
| Electroencephalography | 1 | 2018 | 865 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 552 | 0.100 |
Why?
|
| Malabsorption Syndromes | 1 | 2013 | 36 | 0.100 |
Why?
|
| Histones | 1 | 2016 | 524 | 0.100 |
Why?
|
| Galactose | 2 | 2020 | 54 | 0.100 |
Why?
|
| RNA Helicases | 1 | 2013 | 63 | 0.100 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 103 | 0.100 |
Why?
|
| Reactive Nitrogen Species | 1 | 2012 | 8 | 0.100 |
Why?
|
| Nutritional Support | 1 | 2013 | 55 | 0.100 |
Why?
|
| Endoglin | 1 | 2012 | 21 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 668 | 0.100 |
Why?
|
| Proteins | 2 | 2011 | 1036 | 0.100 |
Why?
|
| North America | 3 | 2022 | 241 | 0.100 |
Why?
|
| Karyotyping | 2 | 2009 | 323 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2016 | 460 | 0.100 |
Why?
|
| Vesicular Acetylcholine Transport Proteins | 1 | 2011 | 5 | 0.100 |
Why?
|
| Argininosuccinate Lyase | 1 | 2012 | 58 | 0.100 |
Why?
|
| Lactic Acid | 2 | 2020 | 153 | 0.100 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 504 | 0.100 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2012 | 80 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2012 | 120 | 0.090 |
Why?
|
| Desmosterol | 1 | 2011 | 3 | 0.090 |
Why?
|
| Nerve Growth Factors | 1 | 2011 | 71 | 0.090 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 256 | 0.090 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2011 | 20 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 337 | 0.090 |
Why?
|
| Holoprosencephaly | 1 | 2011 | 23 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2012 | 219 | 0.090 |
Why?
|
| Acetylcysteine | 2 | 2022 | 72 | 0.090 |
Why?
|
| Muscular Atrophy | 1 | 2012 | 75 | 0.090 |
Why?
|
| Genes | 1 | 2012 | 447 | 0.090 |
Why?
|
| Rhombencephalon | 1 | 2011 | 46 | 0.090 |
Why?
|
| Facies | 3 | 2016 | 153 | 0.090 |
Why?
|
| Survival Rate | 1 | 2016 | 2063 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2013 | 222 | 0.090 |
Why?
|
| Autopsy | 1 | 2011 | 113 | 0.090 |
Why?
|
| Nitrogen | 1 | 2011 | 146 | 0.090 |
Why?
|
| Membrane Transport Proteins | 2 | 2008 | 175 | 0.090 |
Why?
|
| Drosophila melanogaster | 1 | 2016 | 769 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 641 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 2 | 2008 | 395 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2010 | 150 | 0.080 |
Why?
|
| Solute Carrier Family 22 Member 5 | 3 | 2010 | 5 | 0.080 |
Why?
|
| Pathology, Molecular | 1 | 2010 | 58 | 0.080 |
Why?
|
| Glutamine | 1 | 2011 | 215 | 0.080 |
Why?
|
| Glucose | 1 | 2014 | 877 | 0.080 |
Why?
|
| Kidney | 3 | 2019 | 1365 | 0.080 |
Why?
|
| Classical Lissencephalies and Subcortical Band Heterotopias | 1 | 2009 | 14 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 78 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2016 | 860 | 0.080 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 132 | 0.080 |
Why?
|
| X Chromosome Inactivation | 1 | 2009 | 62 | 0.080 |
Why?
|
| Mice | 6 | 2017 | 17632 | 0.080 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2011 | 213 | 0.080 |
Why?
|
| Cytogenetic Analysis | 1 | 2009 | 80 | 0.080 |
Why?
|
| Ovary | 1 | 2012 | 380 | 0.080 |
Why?
|
| 14-3-3 Proteins | 1 | 2009 | 54 | 0.080 |
Why?
|
| Amino Acid Transport Disorders, Inborn | 1 | 2008 | 1 | 0.080 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2009 | 98 | 0.080 |
Why?
|
| Interview, Psychological | 1 | 2009 | 97 | 0.080 |
Why?
|
| Fibroblasts | 4 | 2017 | 878 | 0.080 |
Why?
|
| Fossils | 2 | 2019 | 8 | 0.080 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 221 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2025 | 2913 | 0.070 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2008 | 5 | 0.070 |
Why?
|
| Collodion | 1 | 2008 | 8 | 0.070 |
Why?
|
| Ichthyosiform Erythroderma, Congenital | 1 | 2008 | 4 | 0.070 |
Why?
|
| Inositol | 1 | 2008 | 13 | 0.070 |
Why?
|
| DNA Repair | 1 | 2011 | 585 | 0.070 |
Why?
|
| DNA-Binding Proteins | 4 | 2022 | 2046 | 0.070 |
Why?
|
| Gliosis | 1 | 2008 | 29 | 0.070 |
Why?
|
| Hepatic Encephalopathy | 1 | 2008 | 76 | 0.070 |
Why?
|
| Psychomotor Disorders | 1 | 2007 | 28 | 0.070 |
Why?
|
| Aspartic Acid | 1 | 2008 | 73 | 0.070 |
Why?
|
| Schwann Cells | 1 | 2008 | 57 | 0.070 |
Why?
|
| Double-Blind Method | 2 | 2023 | 1637 | 0.070 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2008 | 80 | 0.070 |
Why?
|
| Microcirculation | 1 | 2008 | 96 | 0.070 |
Why?
|
| Oligosaccharides | 1 | 2008 | 75 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2009 | 603 | 0.070 |
Why?
|
| Gene Expression | 2 | 2010 | 1561 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 369 | 0.070 |
Why?
|
| Amino Acid Transport Systems, Neutral | 1 | 2007 | 7 | 0.070 |
Why?
|
| DNA Helicases | 2 | 2022 | 231 | 0.070 |
Why?
|
| Turner Syndrome | 1 | 2007 | 45 | 0.070 |
Why?
|
| Nerve Degeneration | 1 | 2008 | 121 | 0.070 |
Why?
|
| Physicians | 1 | 2013 | 587 | 0.070 |
Why?
|
| Neoplasms | 2 | 2011 | 2794 | 0.070 |
Why?
|
| Celiac Disease | 1 | 2007 | 67 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2005 | 345 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2019 | 4534 | 0.070 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2008 | 241 | 0.070 |
Why?
|
| Chromosome Banding | 2 | 2011 | 138 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 716 | 0.060 |
Why?
|
| Phylogeny | 2 | 2019 | 696 | 0.060 |
Why?
|
| Hydroxocobalamin | 2 | 2017 | 9 | 0.060 |
Why?
|
| Gestational Age | 2 | 2021 | 1164 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2025 | 3429 | 0.060 |
Why?
|
| Neuroglia | 1 | 2008 | 204 | 0.060 |
Why?
|
| Sulfurtransferases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Disease Models, Animal | 3 | 2019 | 4392 | 0.060 |
Why?
|
| Metalloproteins | 1 | 2005 | 11 | 0.060 |
Why?
|
| Consensus | 2 | 2022 | 641 | 0.060 |
Why?
|
| Echocardiography | 1 | 2011 | 1055 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2005 | 54 | 0.060 |
Why?
|
| Methylmalonic Acid | 1 | 2005 | 15 | 0.060 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2005 | 20 | 0.060 |
Why?
|
| Creatine Kinase | 1 | 2005 | 58 | 0.060 |
Why?
|
| Mitochondria, Muscle | 1 | 2005 | 34 | 0.060 |
Why?
|
| Carbamoyl-Phosphate Synthase I Deficiency Disease | 1 | 2004 | 5 | 0.060 |
Why?
|
| Axons | 1 | 2008 | 369 | 0.060 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 123 | 0.060 |
Why?
|
| Dementia | 1 | 2010 | 452 | 0.060 |
Why?
|
| alpha-Synuclein | 1 | 2005 | 122 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2004 | 30 | 0.060 |
Why?
|
| Argininosuccinic Aciduria | 1 | 2004 | 47 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2009 | 593 | 0.060 |
Why?
|
| Thrombosis | 1 | 2009 | 525 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2011 | 783 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2005 | 187 | 0.060 |
Why?
|
| Goals | 1 | 2025 | 128 | 0.060 |
Why?
|
| Citrullinemia | 1 | 2004 | 15 | 0.060 |
Why?
|
| Phenylacetates | 1 | 2004 | 23 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2007 | 1700 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 343 | 0.060 |
Why?
|
| Ataxins | 1 | 2004 | 114 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 232 | 0.050 |
Why?
|
| Risk Factors | 2 | 2016 | 10309 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2005 | 410 | 0.050 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2006 | 309 | 0.050 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2023 | 10 | 0.050 |
Why?
|
| Tyrosine | 1 | 2003 | 154 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2007 | 469 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2003 | 248 | 0.050 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 271 | 0.050 |
Why?
|
| Carrier State | 1 | 2003 | 76 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 395 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 173 | 0.050 |
Why?
|
| Orotic Acid | 1 | 2002 | 3 | 0.050 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2004 | 125 | 0.050 |
Why?
|
| Insulin | 2 | 2014 | 1203 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 1112 | 0.050 |
Why?
|
| Myocardium | 2 | 2007 | 1016 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 2056 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2005 | 445 | 0.050 |
Why?
|
| Cause of Death | 1 | 2025 | 475 | 0.050 |
Why?
|
| Tyrosinemias | 1 | 2002 | 5 | 0.050 |
Why?
|
| Aged | 4 | 2025 | 19871 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 2007 | 514 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2174 | 0.050 |
Why?
|
| Lipids | 1 | 2005 | 522 | 0.050 |
Why?
|
| Sequence Alignment | 1 | 2003 | 621 | 0.050 |
Why?
|
| Fatigue | 1 | 2023 | 190 | 0.050 |
Why?
|
| Pelizaeus-Merzbacher Disease | 1 | 2001 | 22 | 0.050 |
Why?
|
| Myelin Proteolipid Protein | 1 | 2001 | 27 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1694 | 0.050 |
Why?
|
| Membrane Potentials | 2 | 2001 | 306 | 0.050 |
Why?
|
| Kinetics | 2 | 2005 | 1332 | 0.050 |
Why?
|
| Sodium | 2 | 2001 | 297 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 684 | 0.050 |
Why?
|
| Neck | 1 | 2022 | 135 | 0.050 |
Why?
|
| Family Health | 1 | 2002 | 259 | 0.050 |
Why?
|
| Exercise | 2 | 2020 | 816 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 2001 | 215 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2004 | 1506 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2002 | 399 | 0.040 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2022 | 209 | 0.040 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2001 | 102 | 0.040 |
Why?
|
| Cholesterol, HDL | 1 | 2022 | 358 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 1170 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2002 | 124 | 0.040 |
Why?
|
| Monosomy | 1 | 2000 | 24 | 0.040 |
Why?
|
| Porphyria, Acute Intermittent | 1 | 2000 | 2 | 0.040 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 2000 | 5 | 0.040 |
Why?
|
| Esophageal Motility Disorders | 1 | 2020 | 17 | 0.040 |
Why?
|
| Phenylketonurias | 1 | 2000 | 13 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 1999 | 12 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1695 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2017 | 1688 | 0.040 |
Why?
|
| Acidosis | 1 | 2021 | 93 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2022 | 347 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 101 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2024 | 4821 | 0.040 |
Why?
|
| Nephrons | 1 | 2019 | 20 | 0.040 |
Why?
|
| Acetylcarnitine | 1 | 1999 | 1 | 0.040 |
Why?
|
| Palmitoylcarnitine | 1 | 1999 | 6 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 880 | 0.040 |
Why?
|
| Paternal Inheritance | 1 | 2019 | 9 | 0.040 |
Why?
|
| Cricetulus | 1 | 2019 | 101 | 0.040 |
Why?
|
| Xenopus laevis | 1 | 2019 | 126 | 0.040 |
Why?
|
| Betaine | 1 | 1999 | 22 | 0.040 |
Why?
|
| Serologic Tests | 1 | 1999 | 118 | 0.040 |
Why?
|
| Maternal Inheritance | 1 | 2019 | 13 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1999 | 192 | 0.040 |
Why?
|
| CHO Cells | 1 | 2019 | 169 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 35 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 115 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 2064 | 0.040 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 124 | 0.040 |
Why?
|
| Urinary Tract | 1 | 2019 | 60 | 0.040 |
Why?
|
| Genome, Human | 2 | 2017 | 1272 | 0.040 |
Why?
|
| Muscles | 1 | 2019 | 292 | 0.040 |
Why?
|
| Exercise Test | 1 | 2020 | 254 | 0.040 |
Why?
|
| Organogenesis | 1 | 2019 | 80 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2008 | 61 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 1999 | 443 | 0.040 |
Why?
|
| Potassium | 1 | 1999 | 282 | 0.040 |
Why?
|
| Progeria | 1 | 2017 | 16 | 0.040 |
Why?
|
| Cutis Laxa | 1 | 2017 | 11 | 0.040 |
Why?
|
| Infant Care | 1 | 2017 | 46 | 0.040 |
Why?
|
| Mitochondrial Membranes | 1 | 2017 | 30 | 0.040 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2017 | 51 | 0.040 |
Why?
|
| Heart Defects, Congenital | 1 | 2009 | 1824 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 332 | 0.040 |
Why?
|
| South America | 1 | 2017 | 39 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2017 | 92 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1999 | 224 | 0.030 |
Why?
|
| Time Factors | 2 | 2005 | 6334 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2001 | 444 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2017 | 112 | 0.030 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2017 | 31 | 0.030 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2017 | 67 | 0.030 |
Why?
|
| Heart Rate | 1 | 2020 | 592 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2000 | 760 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2019 | 474 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 282 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 2017 | 101 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2017 | 346 | 0.030 |
Why?
|
| Corneal Opacity | 1 | 2016 | 23 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 166 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2017 | 220 | 0.030 |
Why?
|
| Obesity | 1 | 2007 | 2248 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2017 | 201 | 0.030 |
Why?
|
| Coloboma | 1 | 2016 | 45 | 0.030 |
Why?
|
| Arabs | 1 | 2016 | 29 | 0.030 |
Why?
|
| Lysine | 1 | 2016 | 196 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1696 | 0.030 |
Why?
|
| Growth Disorders | 1 | 2017 | 209 | 0.030 |
Why?
|
| Histone Acetyltransferases | 1 | 2016 | 314 | 0.030 |
Why?
|
| Golgi Apparatus | 1 | 2016 | 93 | 0.030 |
Why?
|
| Registries | 1 | 2022 | 1433 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2017 | 239 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2006 | 6600 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 179 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 2522 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2016 | 121 | 0.030 |
Why?
|
| Iron | 1 | 2017 | 270 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 658 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 237 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2016 | 271 | 0.030 |
Why?
|
| Codon, Nonsense | 1 | 2015 | 131 | 0.030 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2015 | 82 | 0.030 |
Why?
|
| Isotope Labeling | 1 | 2014 | 105 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Gluconeogenesis | 1 | 2014 | 106 | 0.030 |
Why?
|
| Oculocerebrorenal Syndrome | 1 | 2013 | 7 | 0.030 |
Why?
|
| Multifunctional Enzymes | 1 | 2013 | 5 | 0.030 |
Why?
|
| Xenobiotics | 1 | 2013 | 26 | 0.030 |
Why?
|
| Nephrolithiasis | 1 | 2013 | 14 | 0.030 |
Why?
|
| Nicaragua | 1 | 2013 | 26 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2014 | 209 | 0.030 |
Why?
|
| Spinocerebellar Degenerations | 1 | 2013 | 64 | 0.030 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2013 | 64 | 0.030 |
Why?
|
| DNA | 2 | 2009 | 1608 | 0.030 |
Why?
|
| Vitamins | 1 | 2013 | 108 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2013 | 101 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2013 | 66 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1396 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 822 | 0.030 |
Why?
|
| DNA Polymerase gamma | 1 | 2012 | 10 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2013 | 122 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2017 | 838 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 657 | 0.020 |
Why?
|
| Ovarian Diseases | 1 | 2012 | 28 | 0.020 |
Why?
|
| Length of Stay | 1 | 2017 | 1310 | 0.020 |
Why?
|
| Diet | 1 | 1999 | 1140 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2013 | 367 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2013 | 338 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2011 | 64 | 0.020 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 8 | 0.020 |
Why?
|
| Age Determination by Skeleton | 1 | 2011 | 9 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 1201 | 0.020 |
Why?
|
| Cell Membrane | 2 | 2005 | 462 | 0.020 |
Why?
|
| 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 1 | 2011 | 21 | 0.020 |
Why?
|
| Homologous Recombination | 1 | 2011 | 92 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 102 | 0.020 |
Why?
|
| Haplotypes | 1 | 2013 | 522 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1782 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 70 | 0.020 |
Why?
|
| Heart Failure | 1 | 2004 | 2297 | 0.020 |
Why?
|
| Lung | 1 | 2019 | 1496 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 635 | 0.020 |
Why?
|
| Chromosome Breakpoints | 1 | 2010 | 80 | 0.020 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2011 | 104 | 0.020 |
Why?
|
| Siblings | 1 | 2011 | 196 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1241 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 81 | 0.020 |
Why?
|
| GATA4 Transcription Factor | 1 | 2009 | 35 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2014 | 640 | 0.020 |
Why?
|
| Compartment Syndromes | 1 | 2009 | 31 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2011 | 834 | 0.020 |
Why?
|
| Enoxaparin | 1 | 2009 | 42 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3588 | 0.020 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2009 | 92 | 0.020 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2009 | 48 | 0.020 |
Why?
|
| Apoptosis | 2 | 2007 | 1806 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2016 | 3744 | 0.020 |
Why?
|
| Survivors | 1 | 2011 | 339 | 0.020 |
Why?
|
| Contraindications | 1 | 2008 | 78 | 0.020 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2008 | 7 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2012 | 1079 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2011 | 930 | 0.020 |
Why?
|
| Ornithine Carbamoyltransferase | 1 | 2008 | 17 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 224 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2011 | 426 | 0.020 |
Why?
|
| Dystrophin | 1 | 2008 | 39 | 0.020 |
Why?
|
| Hirsutism | 1 | 2007 | 20 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2821 | 0.020 |
Why?
|
| Italy | 1 | 2007 | 100 | 0.020 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2008 | 56 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 4404 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 1398 | 0.020 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2007 | 53 | 0.020 |
Why?
|
| Live Birth | 1 | 2007 | 55 | 0.020 |
Why?
|
| Herpes Simplex Virus Protein Vmw65 | 1 | 2007 | 8 | 0.020 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2007 | 7 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 183 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 190 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2008 | 428 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 2011 | 1314 | 0.020 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2007 | 86 | 0.020 |
Why?
|
| Family | 1 | 2010 | 566 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 1271 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 128 | 0.020 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2005 | 5 | 0.020 |
Why?
|
| Diphenylhexatriene | 1 | 2005 | 1 | 0.020 |
Why?
|
| Phosphatidylglycerols | 1 | 2005 | 6 | 0.020 |
Why?
|
| Georgia | 1 | 2005 | 30 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2005 | 42 | 0.020 |
Why?
|
| Palmitic Acid | 1 | 2005 | 34 | 0.020 |
Why?
|
| Carbon-Carbon Lyases | 1 | 2005 | 2 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2007 | 313 | 0.020 |
Why?
|
| Pteridines | 1 | 2005 | 8 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 311 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1056 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2005 | 88 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 309 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2005 | 16 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 82 | 0.020 |
Why?
|
| Phospholipids | 1 | 2005 | 106 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2005 | 220 | 0.010 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Nuclear Respiratory Factors | 1 | 2004 | 8 | 0.010 |
Why?
|
| NF-E2-Related Factor 1 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Methionine | 1 | 2005 | 102 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 657 | 0.010 |
Why?
|
| Homocysteine | 1 | 2005 | 123 | 0.010 |
Why?
|
| Cell Survival | 1 | 2007 | 813 | 0.010 |
Why?
|
| Cyclin T | 1 | 2004 | 34 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2007 | 1257 | 0.010 |
Why?
|
| RNA Polymerase II | 1 | 2004 | 100 | 0.010 |
Why?
|
| Cyclins | 1 | 2004 | 101 | 0.010 |
Why?
|
| Mass Screening | 1 | 2010 | 784 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2005 | 1101 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2007 | 795 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2004 | 628 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1629 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2007 | 1631 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 1757 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 1290 | 0.010 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2001 | 23 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2001 | 59 | 0.010 |
Why?
|
| Rubidium | 1 | 2001 | 5 | 0.010 |
Why?
|
| Phorbol 12,13-Dibutyrate | 1 | 2001 | 8 | 0.010 |
Why?
|
| Bumetanide | 1 | 2001 | 7 | 0.010 |
Why?
|
| Ouabain | 1 | 2001 | 28 | 0.010 |
Why?
|
| Oligodendroglia | 1 | 2001 | 76 | 0.010 |
Why?
|
| Androstadienes | 1 | 2001 | 49 | 0.010 |
Why?
|
| Prevalence | 1 | 2007 | 2456 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2001 | 261 | 0.010 |
Why?
|
| Myelin Sheath | 1 | 2001 | 122 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 1329 | 0.010 |
Why?
|
| Carcinogens | 1 | 2001 | 152 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2004 | 797 | 0.010 |
Why?
|
| Diuretics | 1 | 2001 | 171 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 2396 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2004 | 626 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 2005 | 690 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 581 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 3716 | 0.010 |
Why?
|
| Neurons | 1 | 2005 | 1932 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 2106 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1660 | 0.010 |
Why?
|